Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Bumma, N., Richter, J., Brayer, J., Zonder, J. A., Dhodapkar, M., Shah, M. R., Hoffman, J. E., Mawad, R., Maly, J. J., Lentzsch, S., Suvannasankha, A., Roy, P., Dey, J., Chokshi, D., Boyapati, A., Visich, J., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., & Jagannath, S. (2022). Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study. Blood, 140(Supplement 1), 10140–10141. https://doi.org/10.1182/blood-2022-159969
Authors:
Naresh Bumma
Joshua Richter
Jason Brayer
Jeffrey A. Zonder
Madhav V. Dhodapkar
Mansi Shah
James E. Hoffman
Raya Mawad
Joseph Maly
Suzanne Lentzsch
Attaya Suvannasankha
Pourab Roy
Jyotirmoy Dey
Dhruti Chokshi
Anita Boyapati
Jenn Visich
Yariv Houvras
Karen Rodriguez Lorenc
Glenn Kroog
Sundar Jagannath
Affiliated Authors:
Suzanne Lentzsch
Publication Type:
Article
Unique ID:
10.1182/blood-2022-159969
Journal:
Publication Date:
Data Source:
OpenAlex

Record Created: